{"groups":[{"description":"Patients receive 175 mg/m2 paclitaxel IV over 3 hours on day 1, carboplatin AUC 5 IV over 30 minutes on day 1, and 850 mg metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Arm I (Paclitaxel, Carboplatin, Metformin Hydrochloride)"},{"description":"Patients receive 175 mg/m2 paclitaxel IV and carboplatin AUC 5 IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG001","title":"Arm II (Paclitaxel, Carboplatin, Placebo)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"234"},{"groupId":"FG001","numSubjects":"235"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"234"},{"groupId":"FG001","numSubjects":"235"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}